Quintiles.com

  • Contact quintiles

    Phone:+1 866 267 4479


    Request a Proposal

  • Therapeutic Expertise Infectious Diseases

  • clinical-trials-header
  • Quintiles Clinical Trial

    The threat of infectious disease is real, and it’s growing fast – sometimes faster than biopharma’s ability to respond.

    Old standards like influenza, malaria and tuberculosis are re-emerging as a danger to public health, while modern foes like H1N1 and HIV-AIDS present new and ongoing challenges. Add to that the increase in drug-resistant microorganisms, the global spread of infectious disease and the threat of bioterrorism, and complexity increases.

    Infectious Diseases

    How do you get desperately needed new treatments and antimicrobial agents to market in a timely, cost-effective manner? Partner with a leader who has a track record in infectious diseases, from influenza to tuberculosis.

    The numbers tell the story. Our experience in the past five years alone includes:

    • 260 clinical infectious disease studies (non-vaccine)
    • 98,000 subjects
    • 10,8000 investigator sites
    • 70 countries

    What does this mean for you? Rapid enrollment during peak illness seasons. Large, worldwide patient recruitment. Expert monitoring of complex studies of long duration. Global regulatory compliance. And the best chance of success for your product.

  • Infectious Disease Experience that Delivers

  • Quintiles Clinical Trails

    Dr. Kelly McKee explores the multi-faceted research in pharmacobiomics and how it will shape the future of pharma and biotech product development. New knowledge is leading to more effective approaches to drug and vaccine development — improving product and process.
    Read white paper

  • Quintiles Clinical Trails

    With the outbreak of the H1N1 virus or “swine flu” in early 2009, the world held its breath, remembering past problems with production and delivery. This white paper offers a detailed look at the history of flu vaccine production and how previous outbreaks set the stage for a comprehensive global response to the H1N1 pandemic.
    Read white paper